Home / Deep Research / Mediator Complex Neurodevelopmental Disorder

Mediator Complex Neurodevelopmental Disorder

Mediator Complex Neurodevelopmental Disorder (MEDopathies): Disease Characteristics Report

2026-04-11
Falcon MONDO:0002320 Model: Edison Scientific Literature 23 citations

Mediator Complex Neurodevelopmental Disorder (MEDopathies): Disease Characteristics Report

Executive summary

“Mediator Complex Neurodevelopmental Disorder” is best understood as an umbrella of monogenic neurodevelopmental disorders caused by pathogenic variants in genes encoding subunits of the RNA polymerase II Mediator complex (often termed MEDopathies or Neuro‑MEDopathies). The most clearly identifiable disease entity in the retrieved 2023–2024 evidence is MED13L haploinsufficiency syndrome (MRFACD; OMIM/MIM #616789; ORPHA:369891). Other closely related entities in the retrieved evidence include MED13-associated intellectual developmental disorder (MRD61), recessive MED23‑related MRT18, and recessive MED27‑related ponto‑cerebello‑lental degeneration. (maroofian2023biallelicmed27variants pages 3-4, siavriene2023molecularandfunctional pages 1-2, plassche2021med12related(neuro)developmentaldisorders pages 1-3)

A high-value 2023–2024 theme is that sequence-level interpretation and functional follow-up (e.g., transcript/protein assays, cell models) are increasingly used to support pathogenicity and refine genotype–phenotype correlations, while patient-advocacy organizations are explicitly organizing trial-readiness roadmaps (e.g., MED13L Foundation 2024 strategic research plan). (siavriene2023molecularandfunctional pages 1-2, heilmann2024themed13lfoundation pages 1-1)

1. Disease information

1.1 What is the disease?

Mediator complex neurodevelopmental disorders (MEDopathies) are neurodevelopmental conditions resulting from disrupted Mediator complex function, leading to dysregulated RNA polymerase II–dependent transcription programs important for brain development. Mechanistically, Mediator is described as “a large, evolutionarily conserved multiprotein complex” that “plays a critical role in facilitating transcriptional regulation by acting as a physical and functional bridge between DNA‑binding transcription factors and the transcriptional machinery.” (maroofian2023biallelicmed27variants pages 3-4)

Because clinical usage and coding tend to be gene-centric, this umbrella is most actionable in practice as a set of gene-defined syndromes (e.g., MED13L syndrome/MRFACD; MED12 syndromes; MED27 recessive neurodegeneration/NDD). (maroofian2023biallelicmed27variants pages 3-4, plassche2021med12related(neuro)developmentaldisorders pages 1-3, siavriene2023molecularandfunctional pages 1-2)

1.2 Key identifiers (as available in retrieved sources)

Not found in retrieved evidence: MONDO ID, ICD‑10/ICD‑11 code, MeSH descriptor for a single umbrella entity. (siavriene2023molecularandfunctional pages 1-2)

1.3 Common synonyms/alternative names

1.4 Evidence sources (individual vs aggregated)

The retrieved evidence is primarily: - Case reports/case series and genotype-first matchmaker collaborations (MED13, MED23, MED27, MED13L). (tolmacheva2024expandingphenotypeof pages 1-2, salzano2023casereportnovel pages 1-2, maroofian2023biallelicmed27variants pages 3-4) - Aggregated research programs/registries: Simons Searchlight (large prospective observational program including MED13L and MED13). (NCT01238250 chunk 1, NCT01238250 chunk 2) - Patient-advocacy strategic planning for trial readiness: MED13L Foundation SRP (2024). (heilmann2024themed13lfoundation pages 1-1)

2. Etiology

2.1 Disease causal factors

Primary causal factors are germline pathogenic variants in genes encoding Mediator complex subunits. The causal chain is typically: variant → altered Mediator subunit abundance/function/localization → altered Pol II transcriptional regulation → disrupted neurodevelopmental programs → developmental delay/ID and syndromic features. (maroofian2023biallelicmed27variants pages 3-4, plassche2021med12related(neuro)developmentaldisorders pages 1-3, hamada2023med13landits pages 2-2)

2.2 Risk factors

2.3 Protective factors / gene–environment interactions

No protective variants or robust gene–environment interactions were identified in the retrieved evidence for these Mendelian conditions. (siavriene2023molecularandfunctional pages 1-2)

3. Phenotypes (clinical features)

3.1 Cross-MEDopathy phenotype themes

Across Mediator-subunit disorders, convergent features include global developmental delay/intellectual disability, hypotonia, epilepsy, speech disorders, and behavioral comorbidity, with additional gene-specific systemic features (e.g., cataracts in MED27; congenital anomalies in MED13 and MED13L). (maroofian2023biallelicmed27variants pages 3-4, fazio2025geneticclinicaland pages 22-24)

3.2 MED13L haploinsufficiency syndrome (MRFACD; OMIM/MIM #616789)

A 2023 MED13L paper succinctly states: “Heterozygous pathogenic variants in the MED13L gene cause impaired intellectual development and distinctive facial features with or without cardiac defects (MIM #616789).” (siavriene2023molecularandfunctional pages 1-2)

Typical features described across MED13L sources include: - Neurodevelopment: intellectual disability/developmental delay; marked speech delay/poor speech (siavriene2023molecularandfunctional pages 1-2, bessenyei2022med13lrelatedintellectualdisability pages 1-2) - Neuromuscular: hypotonia; motor delay (bessenyei2022med13lrelatedintellectualdisability pages 1-2) - Craniofacial gestalt/dysmorphism: “distinctive facial features” (siavriene2023molecularandfunctional pages 1-2) - Variable congenital anomalies: plagiocephaly, strabismus, clubfoot (siavriene2023molecularandfunctional pages 1-2) - Cardiac: variable congenital heart defects (“with or without cardiac defects”) (siavriene2023molecularandfunctional pages 1-2)

Suggested HPO terms (non-exhaustive, mapped to the described features): - Intellectual disability: HP:0001249 - Global developmental delay: HP:0001263 - Speech delay / severe expressive language impairment: HP:0000750, HP:0002463 - Hypotonia: HP:0001252 - Strabismus: HP:0000486 - Plagiocephaly: HP:0001357 - Talipes equinovarus (clubfoot): HP:0001762 - Congenital heart defect: HP:0001627

3.3 MED27-related disease: quantitative phenotype frequencies

A 2023 Brain cohort study (57 affected individuals, 30 families) reports a broad continuum from developmental epileptic-dyskinetic encephalopathy to variable NDD with movement abnormalities and provides quantitative frequencies, e.g., global developmental delay/intellectual disability (100%), bilateral cataracts (89%), infantile hypotonia (74%), microcephaly (62%), gait ataxia (63%), dystonia (61%), epilepsy (50%), limb spasticity (51%), and death before adulthood (16%); MRI features include cerebellar atrophy (100%) and white matter volume loss (76.4%). (maroofian2023biallelicmed27variants pages 3-4)

Visual evidence for these frequencies is captured from the paper’s Table/Figure. (maroofian2023biallelicmed27variants media 55f96031, maroofian2023biallelicmed27variants media 45999b07)

Suggested HPO terms: cataract (HP:0000518), cerebellar atrophy (HP:0001272), dystonia (HP:0001332), spasticity (HP:0001257), epilepsy (HP:0001250), microcephaly (HP:0000252), ataxia (HP:0001251).

3.4 MED23-related MRT18 (autosomal recessive)

A 2023 case report/review states: “Biallelic loss-of-function variants in MED23 cause a recessive syndromic intellectual disability condition with or without epilepsy (MRT18).” and highlights postnatal progressive microcephaly as an underappreciated feature. (salzano2023casereportnovel pages 1-2)

Suggested HPO terms: autosomal recessive inheritance (HP:0000007), progressive microcephaly (HP:0000253), seizures (HP:0001250), hypotonia (HP:0001252), spasticity (HP:0001257), dystonia (HP:0001332).

3.5 MED13-associated NDD (MRD61): 2024 phenotype expansion

A 2024 BMC Medical Genomics case report describes an infant with a de novo MED13 missense variant identified by trio WES and proposes expanding the MED13-associated phenotype to include severe multisystem findings and neonatal death in rare cases. (tolmacheva2024expandingphenotypeof pages 1-2)

4. Genetic / molecular information

4.1 Causal genes (representative, from retrieved evidence)

A compact map is provided in the table below.

Table (click to expand)
Gene Disorder name(s) / synonyms Key identifier(s) Inheritance pattern Hallmark phenotypes (with frequencies if reported) Key references
MED13L MED13L haploinsufficiency syndrome; MED13L-related intellectual disability; MRFACD (mental retardation and distinctive facial features with or without cardiac defects) MIM/OMIM #616789; ORPHA:369891; gene MED13L MIM 608771 Autosomal dominant, usually de novo heterozygous LoF/CNV; parental mosaicism reported Core syndrome includes intellectual disability/developmental delay, marked speech delay/poor speech, hypotonia, motor delay, characteristic facial gestalt, with cardiac defects variably present; 2023 functional study also lists plagiocephaly, strabismus, clubfoot, macrostomia; review notes missense variants may be more severe and associated with epilepsy/absent speech/walking; one review states ~one-third of reported pathogenic events are large CNVs; no robust pooled prevalence of CHD or speech impairment was given in the gathered evidence (siavriene2023molecularandfunctional pages 1-2, tørring2019ismed13lrelatedintellectual pages 1-5, bessenyei2022med13lrelatedintellectualdisability pages 1-2, fazio2025geneticclinicaland pages 11-13) Siavrienė et al. 2023, Medicina, doi:10.3390/medicina59071225, https://doi.org/10.3390/medicina59071225, PMID: ; Tørring et al. 2019, Eur J Med Genet, doi:10.1016/j.ejmg.2018.06.014, https://doi.org/10.1016/j.ejmg.2018.06.014, PMID: ; Bessenyei et al. 2022, Cold Spring Harb Mol Case Stud, doi:10.1101/mcs.a006124, https://doi.org/10.1101/mcs.a006124, PMID: (siavriene2023molecularandfunctional pages 1-2, tørring2019ismed13lrelatedintellectual pages 1-5, bessenyei2022med13lrelatedintellectualdisability pages 1-2, fazio2025geneticclinicaland pages 11-13)
MED13 MED13-associated neurodevelopmental disorder; intellectual developmental disorder-61 / MRD61 gene MED13 OMIM/MIM 603808; disorder termed MRD61 in later literature Predominantly autosomal dominant, largely de novo heterozygous variants; inherited transmission from affected mother also reported Universal DD/ID in original cohort; prominent speech/language delay, autism/ADHD in some, hypotonia, optic nerve/vision abnormalities, Duane anomaly, mild congenital heart anomalies, dysmorphism; variant types include truncating, missense, in-frame deletion; 2024 neonatal case expanded phenotype to hydrocephalic changes, hypoplastic corpus callosum, optic nerve/chiasm atrophy, brainstem atrophy, multiple organ failure/neonatal death (tolmacheva2024expandingphenotypeof pages 1-2) Blok et al. 2018, Hum Genet, doi:10.1007/s00439-018-1887-y, https://doi.org/10.1007/s00439-018-1887-y, PMID: ; Tolmacheva et al. 2024, BMC Med Genomics, doi:10.1186/s12920-024-01857-z, https://doi.org/10.1186/s12920-024-01857-z, PMID: (tolmacheva2024expandingphenotypeof pages 1-2)
MED23 MED23-related intellectual disability; MRT18; recessive syndromic intellectual disability with/without epilepsy MED23 MIM 605042; MRT18 Autosomal recessive, biallelic pathogenic variants Classical phenotype includes global DD/ID, microcephaly, axial hypotonia, spasticity, choreoathetosis/dystonia, EEG abnormalities and epilepsy; 2023 report emphasized postnatal progressive microcephaly as an underappreciated feature; due to rarity, phenotype frequencies remain limited (salzano2023casereportnovel pages 1-2) Salzano et al. 2023, Front Neurol, doi:10.3389/fneur.2023.1090082, https://doi.org/10.3389/fneur.2023.1090082, PMID: (salzano2023casereportnovel pages 1-2)
MED27 MED27-associated neurodevelopmental disorder; variable ponto-cerebello-lental degeneration with movement disorders; part of Neuro-MEDopathies gene MED27; no OMIM/ORPHA identifier provided in gathered evidence Autosomal recessive, biallelic pathogenic variants Large 2023 series reported global DD/ID 100%, bilateral cataracts 89%, infantile hypotonia 74%, microcephaly 62%, gait ataxia 63%, dystonia 61%, epilepsy 50%, limb spasticity 51%, facial dysmorphism 38%, death before adulthood 16%; MRI: cerebellar atrophy 100%, white-matter volume loss 76.4%, pontine hypoplasia 47.2%, basal ganglia atrophy/signal changes 44.4% (maroofian2023biallelicmed27variants pages 3-4) Maroofian et al. 2023, Brain, doi:10.1093/brain/awad257, https://doi.org/10.1093/brain/awad257, PMID: (maroofian2023biallelicmed27variants pages 3-4)
MED12 MED12-related disorders including FG syndrome / Opitz-Kaveggia syndrome, Lujan-Fryns syndrome, X-linked Ohdo syndrome (Maat-Kievit-Brunner type), non-syndromic X-linked intellectual disability, and Hardikar syndrome FG syndrome MIM 305450; Lujan-Fryns syndrome MIM 309520; X-linked Ohdo syndrome MIM 300895; gene MED12 at Xq13.1 Mainly X-linked; classically hemizygous inherited missense variants in males from carrier mothers; also de novo missense or truncating variants in females; Hardikar syndrome linked to de novo nonsense/LoF in females Shared features across classical MED12 syndromes include intellectual disability, hypotonia, macrocephaly, hyperactivity/behavioral abnormalities, corpus callosum abnormalities, and characteristic craniofacial features; Hardikar syndrome adds facial clefting, pigmentary retinopathy, biliary anomalies, intestinal malrotation; more C-terminal truncations associated with severe syndromic ID in females (plassche2021med12related(neuro)developmentaldisorders pages 1-3) van de Plassche & de Brouwer 2021, Genes, doi:10.3390/genes12050663, https://doi.org/10.3390/genes12050663, PMID: (plassche2021med12related(neuro)developmentaldisorders pages 1-3)
Multiple Mediator subunits MEDopathies / Neuro-MEDopathies (umbrella term for Mediator-complex neurodevelopmental disorders) Examples listed in gathered evidence: MED11 MIM 612383, MED17 MIM 603810, MED20 MIM 612915, MED23 MIM 605042, MED25 MIM 610197, MED12L MIM 611318, MED13 MIM 603808, MED13L Mixed: AR, AD/de novo, X-linked depending on subunit Convergent features across the group include developmental delay/intellectual disability, hypotonia, epilepsy, speech/language disorder, autism/behavioral comorbidity, and variable structural brain/cardiac anomalies; the Mediator complex acts as a bridge between DNA-binding transcription factors and RNA polymerase II transcriptional machinery (maroofian2023biallelicmed27variants pages 3-4, fazio2025geneticclinicaland pages 24-24) Maroofian et al. 2023, Brain, doi:10.1093/brain/awad257, https://doi.org/10.1093/brain/awad257, PMID: ; Fazio et al. 2025, Genes, doi:10.3390/genes16121444, https://doi.org/10.3390/genes16121444, PMID: (maroofian2023biallelicmed27variants pages 3-4, fazio2025geneticclinicaland pages 24-24)

Table: This table summarizes Mediator-complex neurodevelopmental disorders mentioned in the gathered evidence, highlighting identifiers, inheritance, hallmark phenotypes, and key references. It is useful as a compact disease-entity map for comparing major MEDopathy subtypes relevant to diagnosis and curation.

4.2 Variant classes and functional consequences (examples)

MED13L haploinsufficiency - 2023 intragenic deletion spanning exons 3–10 predicted truncation (frameshift) and haploinsufficiency; functional follow-up after MED13L silencing found “reduced cell viability; an accelerated aging process; and inhibition of the RB1, E2F1, and CCNC gene expression.” (siavriene2023molecularandfunctional pages 1-2)

MED13 (CDK8 module-associated) - A 2018 cohort described truncating and missense variants, with non-truncating variants clustering in regions involved in ubiquitination/degradation (p.Thr326/p.Pro327), supporting variant-class dependent mechanisms. (yang2025anovelframeshift pages 7-7)

5. Environmental information

No specific environmental/lifestyle/infectious contributors were identified in the retrieved evidence for these Mendelian disorders. (siavriene2023molecularandfunctional pages 1-2)

6. Mechanism / pathophysiology

6.1 Core concept: Mediator as transcriptional bridge

The Mediator complex functions as a transcriptional regulator, “acting as a physical and functional bridge between DNA-binding transcription factors and the transcriptional machinery.” (maroofian2023biallelicmed27variants pages 3-4)

6.2 MED13L neurodevelopmental mechanisms (model evidence)

Two lines of mechanistic evidence in the retrieved sources support neuronal roles for MED13L:

1) Developmental expression + synaptic localization (mouse) - MED13L shows developmental stage-dependent expression/localization in mouse brain and “at least partially colocalized with pre- and post-synaptic markers, synaptophysin, and PSD95,” suggesting synaptic involvement. (hamada2021expressionanalysesof pages 1-2)

2) Corticogenesis/dendrite development (in utero electroporation; 2023) - Disease-associated MED13L variants show distinct subcellular localization in cortical neurons (some nuclear accumulation; others cytoplasmic), and a truncation variant was “barely detectable,” consistent with haploinsufficiency. (hamada2023med13landits pages 2-2) - Functionally, MED13L knockdown “abrogated dendritic growth in vivo,” and dendritic growth was rescued by RNAi-resistant wild-type MED13L, but not equivalently by certain disease variants. (hamada2023med13landits pages 2-2)

Suggested GO Biological Process terms (mechanism-aligned): - Regulation of transcription by RNA polymerase II (GO:0006357) - Neuron projection development (GO:0031175) - Dendrite development (GO:0016358) - Synapse organization (GO:0050808)

Suggested Cell Ontology (CL) cell types: - Cortical pyramidal neuron (CL:0000540; used as proxy for “cortical layer II/III pyramidal neurons” described experimentally) (hamada2023med13landits pages 2-2) - Neural progenitor cell (CL:0000047; mechanistically implicated broadly in NDD studies, though not directly quantified in retrieved excerpts)

7. Anatomical structures affected

Primary involvement is the central nervous system. In MED27 disease, neuroimaging commonly shows cerebellar atrophy and additional brainstem/white matter changes. (maroofian2023biallelicmed27variants pages 3-4)

Suggested UBERON terms: - Brain (UBERON:0000955) - Cerebellum (UBERON:0002037) - Cerebral cortex (UBERON:0001851)

8. Temporal development

Most MEDopathies present as early-onset neurodevelopmental disorders (infancy/childhood), with developmental delay and evolving neurologic manifestations (e.g., epilepsy, movement disorder) depending on the gene. (maroofian2023biallelicmed27variants pages 3-4, siavriene2023molecularandfunctional pages 1-2)

9. Inheritance and population

9.1 Inheritance patterns (from retrieved evidence)

9.2 Epidemiology

The retrieved sources do not provide rigorous prevalence/incidence estimates for the umbrella “Mediator Complex Neurodevelopmental Disorder.” For MED13L syndrome, one source notes “roughly a hundred reported cases” and that it is among the more common syndromic intellectual disabilities, but this is not a population prevalence estimate. (bessenyei2022med13lrelatedintellectualdisability pages 1-2)

10. Diagnostics

10.1 Genetic testing approaches in current practice (as reflected in retrieved evidence)

10.2 Emerging/adjacent diagnostics

10.3 Differential diagnosis (examples)

Given shared phenotypes (DD/ID, speech impairment, hypotonia, dysmorphism, congenital anomalies), differential diagnoses include other syndromic NDDs; Mediator-subunit disorders themselves can overlap (e.g., MED13 vs MED13L; MED12 spectrum). (maroofian2023biallelicmed27variants pages 3-4, plassche2021med12related(neuro)developmentaldisorders pages 1-3, tolmacheva2024expandingphenotypeof pages 1-2)

11. Outcome / prognosis

Robust longitudinal survival/functional outcome statistics were not available in the retrieved evidence for the umbrella entity. Notably, MED27 disease includes a reported 16% death before adulthood in a large cohort, underscoring gene-specific prognosis differences within MEDopathies. (maroofian2023biallelicmed27variants pages 3-4)

12. Treatment

12.1 Current management

No disease-modifying therapies for MED13L/MED13/MED23/MED27 disorders were identified in the retrieved sources; management is generally supportive and symptom-directed (developmental therapies; seizure management where applicable). (fazio2025geneticclinicaland pages 22-24, siavriene2023molecularandfunctional pages 1-2)

Suggested MAXO terms (supportive, typical for syndromic NDD): - Developmental therapy / early intervention (MAXO:0000942; proxy) - Speech therapy (MAXO:0000717; proxy) - Physical therapy (MAXO:0000010; proxy) - Antiseizure therapy (MAXO:0000647; proxy)

12.2 2023–2024 translational/trial-readiness developments

  • The MED13L Foundation strategic research plan (SRP) (published Jan 2024) frames clinical-trial readiness as an explicit goal, assessing preclinical tools “largely framed through Food and Drug Administration guidelines for the development of therapeutics from bench to bedside.” (heilmann2024themed13lfoundation pages 1-1)

13. Prevention

Primary prevention is not applicable in the usual public-health sense for de novo Mendelian disorders; prevention is chiefly via genetic counseling and reproductive options.

14. Other species / natural disease

Not addressed in the retrieved evidence.

15. Model organisms

Real-world implementations and applications (2023–2024 emphasis)

1) Clinical sequencing workflows: integration of CNV arrays + WES (often trio) to identify Mediator-subunit etiologies in syndromic NDD/congenital anomalies (demonstrated in MED13L 2023 functional CNV paper and MED13 2024 case). (siavriene2023molecularandfunctional pages 1-2, tolmacheva2024expandingphenotypeof pages 1-2) 2) Research registries: Simons Searchlight is a large, remote, prospective observational program enrolling individuals with gene variants including MED13L and MED13, collecting medical/behavioral/developmental data longitudinally; it reports ~7,000 participants already enrolled and plans up to 100,000. URL: https://simonssearchlight.org/ (trial record first posted 2010-11-10; last update posted 2025-06-06). (NCT01238250 chunk 1, NCT01238250 chunk 2) 3) Trial readiness infrastructure: MED13L Foundation SRP (Jan 2024; Therapeutic Advances in Rare Disease; https://doi.org/10.1177/26330040241290252). (heilmann2024themed13lfoundation pages 1-1)

Notable statistics (from recent studies)

  • MED27 cohort (Brain 2023): DD/ID 100%, bilateral cataracts 89%, hypotonia 74%, microcephaly 62%, gait ataxia 63%, dystonia 61%, epilepsy 50%, death before adulthood 16%; MRI cerebellar atrophy 100%. (maroofian2023biallelicmed27variants pages 3-4, maroofian2023biallelicmed27variants media 55f96031, maroofian2023biallelicmed27variants media 45999b07)
  • MED23 rarity: literature still small; 2023 report notes limited number of reported individuals and variants and highlights postnatal progressive microcephaly. (salzano2023casereportnovel pages 1-2)

Limitations of this report (evidence availability)

  • The retrieved sources did not provide MONDO/ICD/MeSH identifiers for the umbrella “Mediator Complex Neurodevelopmental Disorder.” (siavriene2023molecularandfunctional pages 1-2)
  • Many claims requested by the template (population prevalence/incidence, standardized clinical diagnostic criteria, treatment response rates) were not available in the retrieved evidence and would require targeted retrieval from OMIM/Orphanet pages and additional natural history cohorts beyond the currently retrieved texts. (siavriene2023molecularandfunctional pages 1-2)

References

  1. (maroofian2023biallelicmed27variants pages 3-4): R. Maroofian, R. Kaiyrzhanov, E. Calì, M. Zamani, M. Zaki, Matteo P. Ferla, D. Tortora, Saeid Sadeghian, Saadia Maryam Saadi, Uzma Abdullah, Ehsan Ghayoor Karimiani, S. Efthymiou, G. Yeşil, Shahryar Alavi, Aisha Al Shamsi, H. Tajsharghi, M. Abdel-Hamid, N. Saadi, F. Al Mutairi, Lama Alabdi, C. Beetz, Zafar Ali, M. B. Toosi, S. Rudnik-Schöneborn, Meisam Babaei, P. Isohanni, Jameel Muhammad, Khan Sheraz, Maha Al Shalan, S. Hickey, Daphna Marom, E. Elhanan, M. Kurian, Dana Marafi, A. Saberi, M. Hamid, R. Spaull, Linyan Meng, S. Lalani, S. Maqbool, F. Rahman, J. Seeger, T. Palculict, Tracy Lau, D. Murphy, N. Mencacci, K. Steindl, A. Begemann, A. Rauch, Sinan Akbaş, Aslanger Ayça Dilruba, V. Salpietro, Hammad Yousaf, S. Ben-Shachar, K. Ejeskär, A. A. Al Aqeel, F. High, Amy Armstrong-Javors, Seyed Mohammadsaleh Zahraei, Tahereh Seifi, Jawaher Zeighami, G. Shariati, A. Sedaghat, S. N. Asl, Mohmmad Shahrooei, G. Zifarelli, L. Burglen, C. Ravelli, J. Zschocke, Ulrich A. Schatz, Maryam Ghavideldarestani, W. Kamel, H. Van Esch, A. Hackenberg, Jenny C. Taylor, L. Al-Gazali, P. Bauer, Joseph J Gleeson, F. Alkuraya, J. Lupski, H. Galehdari, Reza Azizimalamiri, Wendy K. Chung, S. Baig, H. Houlden, and M. Severino. Biallelic med27 variants lead to variable ponto-cerebello-lental degeneration with movement disorders. Brain, 146:5031-5043, Jul 2023. URL: https://doi.org/10.1093/brain/awad257, doi:10.1093/brain/awad257. This article has 19 citations and is from a highest quality peer-reviewed journal.

  2. (siavriene2023molecularandfunctional pages 1-2): Evelina Siavrienė, Gunda Petraitytė, Violeta Mikštienė, Živilė Maldžienė, Aušra Sasnauskienė, Vilmantė Žitkutė, Laima Ambrozaitytė, Tautvydas Rančelis, Algirdas Utkus, Vaidutis Kučinskas, and Eglė Preikšaitienė. Molecular and functional characterisation of a novel intragenic 12q24.21 deletion resulting in med13l haploinsufficiency syndrome. Medicina, 59:1225, Jun 2023. URL: https://doi.org/10.3390/medicina59071225, doi:10.3390/medicina59071225. This article has 9 citations.

  3. (plassche2021med12related(neuro)developmentaldisorders pages 1-3): Stijn R. van de Plassche and Arjan P. M. de Brouwer. Med12-related (neuro)developmental disorders: a question of causality. Genes, 12 5:663, Apr 2021. URL: https://doi.org/10.3390/genes12050663, doi:10.3390/genes12050663. This article has 26 citations.

  4. (heilmann2024themed13lfoundation pages 1-1): Rachel Heilmann, Anna Pfalzer, Terry Jo Bichell, Ananya Terala, Alicia Campbell, Dylan Taatjes, Jamal Ghoumid, Chad Grueter, Jennifer Bain, Randy Strich, Vanessa Dias, Kimberly Sokorai, Nicholas Seaver, Kelly Sexton, and Kathleen Boychuck. The med13l foundation strategic research plan: a roadmap to the future. Therapeutic Advances in Rare Disease, Jan 2024. URL: https://doi.org/10.1177/26330040241290252, doi:10.1177/26330040241290252. This article has 9 citations.

  5. (salzano2023casereportnovel pages 1-2): Emanuela Salzano, Marcello Niceta, Simone Pizzi, Francesca Clementina Radio, Martina Busè, Francesca Mercadante, Sabina Barresi, Arturo Ferrara, Cecilia Mancini, Marco Tartaglia, and Maria Piccione. Case report: novel compound heterozygosity for pathogenic variants in med23 in a syndromic patient with postnatal microcephaly. Frontiers in Neurology, Feb 2023. URL: https://doi.org/10.3389/fneur.2023.1090082, doi:10.3389/fneur.2023.1090082. This article has 4 citations and is from a peer-reviewed journal.

  6. (tolmacheva2024expandingphenotypeof pages 1-2): Ekaterina Tolmacheva, Anna S. Bolshakova, Jekaterina Shubina, Margarita S. Rogacheva, Alexey N. Ekimov, Julia L. Podurovskaya, Artem A. Burov, Denis V. Rebrikov, Vladimir G. Bychenko, Dmitry Yu. Trofimov, and Gennady T. Sukhikh. Expanding phenotype of med13-associated syndrome presenting novel de novo missense variant in a patient with multiple congenital anomalies. BMC Medical Genomics, May 2024. URL: https://doi.org/10.1186/s12920-024-01857-z, doi:10.1186/s12920-024-01857-z. This article has 8 citations and is from a peer-reviewed journal.

  7. (bessenyei2022med13lrelatedintellectualdisability pages 1-2): Beáta Bessenyei, István Balogh, Attila Mokánszki, Anikó Ujfalusi, Rolph Pfundt, and Katalin Szakszon. Med13l-related intellectual disability due to paternal germinal mosaicism. Cold Spring Harbor Molecular Case Studies, 8:a006124, Oct 2022. URL: https://doi.org/10.1101/mcs.a006124, doi:10.1101/mcs.a006124. This article has 16 citations and is from a peer-reviewed journal.

  8. (NCT01238250 chunk 1): Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight. Simons Searchlight. 2010. ClinicalTrials.gov Identifier: NCT01238250

  9. (NCT01238250 chunk 2): Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight. Simons Searchlight. 2010. ClinicalTrials.gov Identifier: NCT01238250

  10. (hamada2023med13landits pages 2-2): Nanako Hamada, Ikuko Iwamoto, and Koh‐ichi Nagata. med13l and its disease‐associated variants influence the dendritic development of cerebral cortical neurons in the mammalian brain. Journal of Neurochemistry, 165:334-347, Feb 2023. URL: https://doi.org/10.1111/jnc.15783, doi:10.1111/jnc.15783. This article has 15 citations and is from a domain leading peer-reviewed journal.

  11. (fazio2025geneticclinicaland pages 22-24): Alessandro Fazio, Roberta Leonardi, Lorenzo Aliotta, Manuela Lo Bianco, Gennaro Anastasio, Giuseppe Messina, Corrado Spatola, Pietro Valerio Foti, Stefano Palmucci, Antonio Basile, Martino Ruggieri, and Emanuele David. Genetic, clinical and neuroradiological spectrum of med-related disorders: an updated review. Genes, 16:1444, Dec 2025. URL: https://doi.org/10.3390/genes16121444, doi:10.3390/genes16121444. This article has 1 citations.

  12. (maroofian2023biallelicmed27variants media 55f96031): R. Maroofian, R. Kaiyrzhanov, E. Calì, M. Zamani, M. Zaki, Matteo P. Ferla, D. Tortora, Saeid Sadeghian, Saadia Maryam Saadi, Uzma Abdullah, Ehsan Ghayoor Karimiani, S. Efthymiou, G. Yeşil, Shahryar Alavi, Aisha Al Shamsi, H. Tajsharghi, M. Abdel-Hamid, N. Saadi, F. Al Mutairi, Lama Alabdi, C. Beetz, Zafar Ali, M. B. Toosi, S. Rudnik-Schöneborn, Meisam Babaei, P. Isohanni, Jameel Muhammad, Khan Sheraz, Maha Al Shalan, S. Hickey, Daphna Marom, E. Elhanan, M. Kurian, Dana Marafi, A. Saberi, M. Hamid, R. Spaull, Linyan Meng, S. Lalani, S. Maqbool, F. Rahman, J. Seeger, T. Palculict, Tracy Lau, D. Murphy, N. Mencacci, K. Steindl, A. Begemann, A. Rauch, Sinan Akbaş, Aslanger Ayça Dilruba, V. Salpietro, Hammad Yousaf, S. Ben-Shachar, K. Ejeskär, A. A. Al Aqeel, F. High, Amy Armstrong-Javors, Seyed Mohammadsaleh Zahraei, Tahereh Seifi, Jawaher Zeighami, G. Shariati, A. Sedaghat, S. N. Asl, Mohmmad Shahrooei, G. Zifarelli, L. Burglen, C. Ravelli, J. Zschocke, Ulrich A. Schatz, Maryam Ghavideldarestani, W. Kamel, H. Van Esch, A. Hackenberg, Jenny C. Taylor, L. Al-Gazali, P. Bauer, Joseph J Gleeson, F. Alkuraya, J. Lupski, H. Galehdari, Reza Azizimalamiri, Wendy K. Chung, S. Baig, H. Houlden, and M. Severino. Biallelic med27 variants lead to variable ponto-cerebello-lental degeneration with movement disorders. Brain, 146:5031-5043, Jul 2023. URL: https://doi.org/10.1093/brain/awad257, doi:10.1093/brain/awad257. This article has 19 citations and is from a highest quality peer-reviewed journal.

  13. (maroofian2023biallelicmed27variants media 45999b07): R. Maroofian, R. Kaiyrzhanov, E. Calì, M. Zamani, M. Zaki, Matteo P. Ferla, D. Tortora, Saeid Sadeghian, Saadia Maryam Saadi, Uzma Abdullah, Ehsan Ghayoor Karimiani, S. Efthymiou, G. Yeşil, Shahryar Alavi, Aisha Al Shamsi, H. Tajsharghi, M. Abdel-Hamid, N. Saadi, F. Al Mutairi, Lama Alabdi, C. Beetz, Zafar Ali, M. B. Toosi, S. Rudnik-Schöneborn, Meisam Babaei, P. Isohanni, Jameel Muhammad, Khan Sheraz, Maha Al Shalan, S. Hickey, Daphna Marom, E. Elhanan, M. Kurian, Dana Marafi, A. Saberi, M. Hamid, R. Spaull, Linyan Meng, S. Lalani, S. Maqbool, F. Rahman, J. Seeger, T. Palculict, Tracy Lau, D. Murphy, N. Mencacci, K. Steindl, A. Begemann, A. Rauch, Sinan Akbaş, Aslanger Ayça Dilruba, V. Salpietro, Hammad Yousaf, S. Ben-Shachar, K. Ejeskär, A. A. Al Aqeel, F. High, Amy Armstrong-Javors, Seyed Mohammadsaleh Zahraei, Tahereh Seifi, Jawaher Zeighami, G. Shariati, A. Sedaghat, S. N. Asl, Mohmmad Shahrooei, G. Zifarelli, L. Burglen, C. Ravelli, J. Zschocke, Ulrich A. Schatz, Maryam Ghavideldarestani, W. Kamel, H. Van Esch, A. Hackenberg, Jenny C. Taylor, L. Al-Gazali, P. Bauer, Joseph J Gleeson, F. Alkuraya, J. Lupski, H. Galehdari, Reza Azizimalamiri, Wendy K. Chung, S. Baig, H. Houlden, and M. Severino. Biallelic med27 variants lead to variable ponto-cerebello-lental degeneration with movement disorders. Brain, 146:5031-5043, Jul 2023. URL: https://doi.org/10.1093/brain/awad257, doi:10.1093/brain/awad257. This article has 19 citations and is from a highest quality peer-reviewed journal.

  14. (yang2025anovelframeshift pages 7-7): Qi Yang, Qiang Zhang, Sheng Yi, Gaojie Huang, Xunzhao Zhou, Shang Yi, and Jingsi Luo. A novel frameshift variant in the med13 gene causing intellectual developmental disorder-61 in a chinese family. Frontiers in Pediatrics, Oct 2025. URL: https://doi.org/10.3389/fped.2025.1699544, doi:10.3389/fped.2025.1699544. This article has 1 citations.

  15. (tørring2019ismed13lrelatedintellectual pages 1-5): Pernille Mathiesen Tørring, Martin Jakob Larsen, Charlotte Brasch-Andersen, Lotte Nylandsted Krogh, Maria Kibæk, Lone Laulund, Niels Illum, Ulrike Dunkhase-Heinl, Antje Wiesener, Bernt Popp, Giuseppe Marangi, Tina Duelund Hjortshøj, Jakob Ek, Ida Vogel, Naja Becher, Laura Roos, Marcella Zollino, and Christina Ringmann Fagerberg. Is med13l-related intellectual disability a recognizable syndrome? European journal of medical genetics, 62 2:129-136, Feb 2019. URL: https://doi.org/10.1016/j.ejmg.2018.06.014, doi:10.1016/j.ejmg.2018.06.014. This article has 46 citations and is from a peer-reviewed journal.

  16. (fazio2025geneticclinicaland pages 11-13): Alessandro Fazio, Roberta Leonardi, Lorenzo Aliotta, Manuela Lo Bianco, Gennaro Anastasio, Giuseppe Messina, Corrado Spatola, Pietro Valerio Foti, Stefano Palmucci, Antonio Basile, Martino Ruggieri, and Emanuele David. Genetic, clinical and neuroradiological spectrum of med-related disorders: an updated review. Genes, 16:1444, Dec 2025. URL: https://doi.org/10.3390/genes16121444, doi:10.3390/genes16121444. This article has 1 citations.

  17. (fazio2025geneticclinicaland pages 24-24): Alessandro Fazio, Roberta Leonardi, Lorenzo Aliotta, Manuela Lo Bianco, Gennaro Anastasio, Giuseppe Messina, Corrado Spatola, Pietro Valerio Foti, Stefano Palmucci, Antonio Basile, Martino Ruggieri, and Emanuele David. Genetic, clinical and neuroradiological spectrum of med-related disorders: an updated review. Genes, 16:1444, Dec 2025. URL: https://doi.org/10.3390/genes16121444, doi:10.3390/genes16121444. This article has 1 citations.

  18. (hamada2021expressionanalysesof pages 1-2): Nanako Hamada, Ikuko Iwamoto, Masashi Nishikawa, and Koh-ichi Nagata. Expression analyses of mediator complex subunit 13-like: a responsible gene for neurodevelopmental disorders during mouse brain development. Developmental Neuroscience, 43:43-52, Apr 2021. URL: https://doi.org/10.1159/000515188, doi:10.1159/000515188. This article has 11 citations and is from a peer-reviewed journal.